Talha Badar, Hematology/Oncology Specialist at Mayo Clinic, shared on LinkedIn:
“ASH 2026: 11 AML Oral Abstracts to Watch
With ASH26 approaching, here are AML presentations on my watchlist, spanning frontline therapy, targeted approaches, MRD, and emerging treatment strategies:
- Ivosidenib + intensive chemotherapy in newly diagnosed IDH1-mutated AML, phase 3 (HOVON150/AMLSG29-18)
Abstract 0001 - Gilteritinib vs midostaurin in newly diagnosed FLT3-mutated AML (HOVON156/AMLSG28-18/pasha)
Abstract 56 - Bleximenib in R/R KMT2A-rearranged or NPM1-mutated AML, phase 2 CAMELOT-1
Abstract 661 - Cladribine + LDAC + venetoclax vs 7+3 in newly diagnosed AML age ≥60
Abstract 57 - Discontinuation of HMA + venetoclax in newly diagnosed AML with undetectable MRD
Abstract 1009 - Sonrotoclax + azacitidine across ELN 2024 genetic risk groups in treatment-naive AML unfit for intensive chemotherapy
Abstract 60 - Venetoclax + 3-day multi-frequency decitabine vs AZA + VEN in older adults with newly diagnosed AML
Abstract 1012 - Whole-genome-informed MRD testing, prospective multicenter validation (MEASURE)
Abstract 390 - VEN + AZA vs daunorubicin + cytarabine in young adults with ELN adverse-risk AML, phase 2b
Abstract 1010 - Ziftomenib + gilteritinib in R/R NPM1/FLT3 co-mutated AML, first results from KOMET-008
Abstract 66 - FLAI-G frontline therapy in younger patients with FLT3-mutated AML, phase 2 GIMEMA AML2924
Abstract 903
A particularly interesting year for frontline AML, with randomized comparisons challenging established approaches, expanding targeted therapies, and increasing focus on MRD-guided treatment decisions.
Looking forward to seeing the data and discussions in New Orleans.
Abstract 0001 is currently listed in the ASH press program; oral/plenary status is not yet confirmed.
Which AML abstracts are on your ASH26 watchlist?”
You may also be interested in: